PRISMA – Practical meta-analysis of applying local triamcinolone acetonide injection for stenosis after esophageal cancer surgery
Authors Wang W, Shen Z, Du B, Pang Y
Received 10 May 2018
Accepted for publication 25 June 2018
Published 26 November 2018 Volume 2018:10 Pages 6327—6338
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Kenan Onel
Wu Wang,1 Zhen Shen,2 Baoxin Du,3 Yanyang Pang4
1Laboratory of Tropical Biomedicine and Biotechnology, School of Tropical Medicine and Laboratory Medicine, Hainan Medical University, Haikou, Hainan 570100, China; 2Division of Liver Disease, Huangshi City Hospital of Traditional Chinese Medicine (Infectious Disease Hospital), Edong Healthcare Group, Huangshi, Hubei 435000, China; 3Department of Urology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 402760, China; 4Department of Traditional Chinese Medicine, Hainan Medical University, Haikou, Hainan 570100, China
Objectives: To explore the practical method of endoscopic triamcinolone acetonide (TA) injection immediately after endoscopic surgery and combined with endoscopic dilation (ED) in the management of stenosis after esophageal cancer surgery based on their efficacy and safety.
Methods: A comprehensive search was performed in electronic databases including MEDLINE, EMBASE, the Cochrane Library, Web of Science, and China National Knowledge Infrastructure for possible controlled studies. Meta-analyses of the included studies were completed using Reviewer Manager software and were reported based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Results: Eight randomized studies and five controlled studies containing 575 patients were obtained. In five studies (n=282), TA injected after surgery reduced the risk of stenosis (risk difference [RD] =–0.51, 95% CI [–0.64, –0.39], P<0.01) and the required ED sessions (RD =–3.66, 95% CI [–5.87, –1.46], P<0.01). In eight studies (n=293), TA injection combined with ED reduced the risk of recurrence of stenosis (RD =–0.28, 95% CI [–0.47, –0.08], P<0.01) and the required ED sessions (RD =–0.71, 95% CI [–1.39, –0.04], P<0.05). TA injection therapy did not increase the risk of complications in seven studies (n=380; RD =–0.01, 95% CI [–0.04, 0.02], P=0.53) compared with control.
Conclusion: TA injection therapy after esophageal cancer surgery and combined with ED are both effective and safe in the management of stenosis, as they reduce the risk of stenosis and sequentially the required ED sessions without increasing complications.
Keywords: stenosis, esophageal cancer, surgery, triamcinolone acetonide, meta-analyses
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]